Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$74.20M |
$4.71
+1.18%
|
|
SRTS
Sensus Healthcare, Inc.
Sensus manufactures medical devices and biometric sensing technologies, including SRT therapy systems and related imaging components.
|
$73.75M |
$4.48
+0.90%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$73.43M |
$1.39
+1.46%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$73.25M |
$2.35
+0.21%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$71.65M |
$2.56
+1.99%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$71.61M |
$1.45
+0.69%
|
|
LNSR
LENSAR, Inc.
Direct ophthalmic device product (Ophthalmology Devices) produced by LENSAR via the ALLY robotic cataract laser system.
|
$70.83M |
$5.95
+2.59%
|
|
XGN
Exagen Inc.
Exagen provides diagnostic testing services and operates lab facilities for autoimmune diagnostics.
|
$69.80M |
$3.10
+1.64%
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$69.77M |
$1.68
|
|
VATE
INNOVATE Corp.
MediBeacon and R2 Technologies manufacture medical devices/biometrics (skin therapy devices and transdermal kidney function monitoring).
|
$68.55M |
$5.05
-1.75%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$67.53M |
$1.20
+10.65%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$67.48M |
$0.62
-5.97%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$66.70M |
$14.52
+2.76%
|
|
SOTK
Sono-Tek Corporation
Medical device coatings are a key application (balloon catheters, stents), linking Sono-Tek to Medical Devices & Equipment.
|
$65.66M |
$4.16
-0.72%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$65.22M |
$1.28
+4.92%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$65.21M |
$6.40
+0.79%
|
|
BTMD
biote Corp.
Vertical pellet therapy and related implantable products can be categorized under Medical Devices & Biometrics.
|
$64.77M |
$2.23
+6.43%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$63.75M |
$1.20
+3.02%
|
|
DCGO
DocGo Inc.
DocGo directly provides Home Health & Hospice services, including in-home/mobile healthcare delivery.
|
$63.45M |
$0.65
+10.62%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$63.12M |
$11.88
-3.65%
|
|
JANL
Janel Corporation
Life Sciences subsidiaries provide contract manufacturing services (antibody/reagent production, viral vector production).
|
$61.37M |
$51.73
|
|
LFVN
LifeVantage Corporation
LoveBiome's microbiome/gut-health focus expands into digestive-health supplement opportunities.
|
$60.71M |
$4.79
+4.70%
|
|
LUNG
Pulmonx Corporation
Zephyr Endobronchial Valve and related medical devices are core product offerings.
|
$60.63M |
$1.47
+0.34%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$60.61M |
$4.29
+4.13%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$59.98M |
$6.42
+3.30%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$58.70M |
$1.27
+6.25%
|
Showing page 27 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
